TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
PolyPeptide Laboratories (Sweden) AB
Closing information (x1000 NOK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
1,080,164
|
852,574
|
952,976 |
| Financial expenses |
23,781
|
3,480
|
3,198 |
| Earnings before taxes |
196,418
|
283,427
|
397,798 |
| EBITDA |
262,149
|
263,524
|
408,505 |
| Total assets |
2,017,299
|
1,434,993
|
1,400,232 |
| Current assets |
1,342,478
|
846,887
|
959,630 |
| Current liabilities |
422,634
|
297,763
|
330,318 |
| Equity capital |
1,133,990
|
989,880
|
950,966 |
| - share capital |
11,650
|
10,878
|
11,215 |
| Employees (average) |
312
|
325
|
297 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
56.2%
|
69.0%
|
67.9% |
| Turnover per employee |
3,462
|
2,623
|
3,209 |
| Profit as a percentage of turnover |
18.2%
|
33.2%
|
41.7% |
| Return on assets (ROA) |
10.9%
|
20.0%
|
28.6% |
| Current ratio |
317.6%
|
284.4%
|
290.5% |
| Return on equity (ROE) |
17.3%
|
28.6%
|
41.8% |
| Change turnover |
167,095
|
-71,762
|
239,085 |
| Change turnover % |
18%
|
-8%
|
33% |
| Chg. No. of employees |
-13
|
28
|
31 |
| Chg. No. of employees % |
-4%
|
9%
|
12% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.